agilon health — Value-Based Care Economics Under Severe Stress

agilon health partners with primary care physicians — primarily independent, physician-owned groups serving senior populations — and takes on full-risk Medicare Advantage economics on their behalf. The company provides the infrastructure: payor contracting, actuarial and analytics capabilities, clinical program tooling, and capital to support risk-based arrangements. Revenue is recognized as capitated premium, with medical costs paid to the network and the residual retained as medical margin, supplemented by management fees from partner physicians.

The customer base is dual: health plans that delegate risk to agilon, and the physician groups that participate in agilon's network. Scale is measured in lives — total members under management and, critically, the share of those lives in full-risk arrangements, which carry the highest margin potential and the highest loss potential. The company operates across a portfolio of geographic markets, several of which have been exited or restructured as medical costs exceeded capitation.

At a $2.0B market cap with 16.79M shares outstanding, agilon is now valued at a fraction of the revenue it manages, reflecting the market's view that capitated revenue carries negative economic value at current cost trends.

Near term (next 4–8 quarters). Growth is not the operative variable — margin recovery is. The near-term drivers are (1) the finalized CMS Medicare Advantage rate for the next plan year, (2) repricing of payor contracts to reflect elevated utilization, (3) completion of market exits that remove loss-making lives, and (4) administrative cost reduction. Each of these is a margin event, not a revenue event; revenue may well decline as agilon sheds unprofitable markets, and that decline would be a positive signal.

Medium term (2–4 years). If medical margin normalizes, growth resumes through same-market expansion — adding physicians and lives within existing payor relationships where agilon already has fixed infrastructure — and through conversion of shared-savings lives into full-risk lives. The conversion lever is the highest-value growth available, since incremental full-risk lives carry minimal incremental overhead. The gating factor is physician appetite for risk after a period of losses; partner retention is therefore a leading indicator of medium-term growth.

Historical figures are illustrative of the trajectory implied by reported results; forward figures are analyst estimates. Share count reflects the current 16.79M outstanding figure.

The narrative is one of a spread business inverting. Revenue peaked as agilon added lives aggressively, then declined as markets were exited; simultaneously medical margin went from high single digits to negative as utilization and specialty drug costs outran capitation. The EPS trajectory to -$15.41 reflects both operating losses and the collapse in share count, which mathematically magnifies per-share losses even as absolute losses narrow. The key forward test is whether medical margin crosses back above zero in FY2026E — the single most important line in this table.

The addressable market is the population of Medicare Advantage lives in risk-based arrangements, a multi-hundred-billion-dollar premium pool of which risk-bearing primary care represents a large and growing slice. Structural tailwinds — MA penetration above half of eligible lives, CMS pressure on fee-for-service economics, and physician consolidation — favor the model. The cyclical headwind is that capitation rates lag utilization, and the last several years have been a utilization catch-up cycle that punished every full-risk intermediary.

Competitive positioning: agilon's differentiation is its physician-aligned, market-dense model and its payor-agnostic contracting, versus owned-clinic models that carry heavy fixed assets. Named comparables:

DCF. A discounted cash flow is only marginally useful here because near-term cash flows are negative and terminal value dominates. A reasonable framework: assume medical margin recovers to 2–3% of capitated revenue by the terminal year on roughly $3.4B of revenue, giving $70–100M of pre-tax medical margin, less $80–100M of platform and corporate cost, producing modest positive EBITDA. Applying a 10–12% discount rate and a terminal multiple of 10–12x EBITDA to that normalized figure, and probability-weighting for the risk of a dilutive equity raise or restructuring, yields an intrinsic value range that straddles the current $2.0B market cap. In other words, the market is roughly pricing a successful turnaround with meaningful execution risk remaining.

Comparable multiples. On trailing metrics agilon is not comparable — negative EBITDA and EPS of -$15.41 make multiples meaningless. The relevant comparison is EV/revenue and EV/lives against physician-enablement peers.

At ~0.6x forward revenue, AGL trades in line with a sector median that includes payors trading at trough multiples. A re-rating toward Privia's 1.4x requires demonstrated positive medical margin — the entire thesis in one number.

• Medical cost trend risk. Continued elevation in inpatient, specialty pharmacy, and behavioral utilization against fixed capitation would extend losses and consume remaining liquidity. This is the dominant risk and has already materialized twice.
• Liquidity and dilution risk. With negative EPS and a 16.79M share count, any equity raise is severely dilutive per share; a debt raise may be unavailable on acceptable terms. Covenant or minimum-capital triggers could force action at the worst possible price.
• Payor concentration and contract risk. A small number of health plans delegate risk to agilon; renegotiation, termination, or unfavorable repricing by one large payor would materially impair revenue and margin.
• Float and volatility risk. A 10.93M float, 0.24M average volume, beta of 3.11, and 8.54% short interest mean the shares can move 25% on flow alone, as today demonstrates. Entry and exit prices may bear little relation to fundamental value.
• Regulatory and rate risk. CMS Medicare Advantage rate changes, risk-adjustment methodology revisions, and STAR rating dynamics flow directly into capitation and can shift the entire economics of the model in a single annual cycle.